FOLD News and Press, Amicus Therapeutics Inc. From 02/27/19

AAON , ABB , ACIW , AKRX , AMCX , AMRX , BCPC , BID , BMCH , BPMP , BUD , CARS , CM , CMD , CNP , CROX , CWEN , CWT , DAVA , DEA , EGRX , ENDP , EXLS , FOLD , FRO , FSS , GOLF , GTN , GTT , HMHC , HRI , IBP , ICPT , IRDM , JCP , JD , KDP , LAUR , LKQ ,...

New 75,000 sq. ft. State of the Art Facility in uCity Square Adjacent to Penn Campus Strengthens Amicus Capabilities as a Leading Global Rare Disease Biotechnology Company CRANBURY, N.J. and PHILADELPHIA, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FO...

The FDA has granted  Breakthrough Therapy Designation to Amicus Therapeutics' (NASDAQ: FOLD ) AT-GAA for the treatment of late onset Pompe disease. More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

First BTD Granted for a Second Generation Lysosomal Storage Disorder Therapy First BTD for an Investigational Treatment in Pompe Disease CRANBURY, N.J., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administrat...

Amicus Therapeutics ( FOLD ) received approval for Galafold (migalastat) for Fabry disease in August last year. On Jan. 7, it provided revenue data which showed that Galafold made $91M in those 6 months, beating guidance range of $80-$90M. The company has one other drug in late stage trials ta...

NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD), Clovis Oncology, Inc. (NASDAQ:CL...

CRANBURY, N.J., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 28, 2019 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2018. ...

Amicus Therapeutics (NASDAQ: FOLD ) announces positive 24-month results from a Phase 1/2 clinical trial, ATB200-02 , evaluating AT-GAA in patients with an inherited lysosomal storage disorder called Pompe disease. The data are being presented at the WORLD Symposium in Orlando, FL. More...

Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers Continue for both ERT-Naïve and ERT-Switch Patients Patient Reported Outcomes Data Demonstrate Benefits in Activities of Daily Living and Patient Well Being for AT-GAA Treated Pat...

"A cynic is a man who, when he smells flowers, looks around for a coffin." - H.L. Mencken Stocks ended January on a high note with the major indices up just under one and half percent last week. It was the best start to a New Year since 1987 for investors after a dismal fourth quarter. T...